Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans
- 1 July 1999
- journal article
- clinical trial
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 290 (1) , 136-145
- https://doi.org/10.1016/s0022-3565(24)34877-3
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- Prolactin and cortisol responses to fenfluramine challenge in maniaBiological Psychiatry, 1996
- Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetineEuropean Journal of Clinical Pharmacology, 1994
- Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjectsBiological Psychiatry, 1994
- The effects of gepirone on neuroendocrine function and temperature in humansPsychopharmacology, 1990
- 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primatesBrain Research, 1988
- The Complications of 'Ecstasy' (MDMA)Published by American Medical Association (AMA) ,1988
- 'Eve' and 'Ecstasy'JAMA, 1987
- Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in manPsychopharmacology, 1984
- Fluorescence polarization immunoassay for cortisolClinica Chimica Acta; International Journal of Clinical Chemistry, 1979
- Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in manClinical Pharmacology & Therapeutics, 1971